跳至主要内容
临床试验/EUCTR2007-001831-73-DE
EUCTR2007-001831-73-DE进行中(未招募)不适用

REducing Deaths due to OXidative Stress The REDOXS© Study A 2×2 factorial randomized trial of glutamine and antioxidant supplementation in critically ill patients - REDOXS©

Kingston General Hospital, Queen's University of Kingston0 个研究点目标入组 1,200 人开始时间: 2008年10月13日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
1,200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients must meet ALL inclusion criterias:
  • 1. Signed informed consent has been obtained from the patient or his/her legally acceptable representative
  • 2. Mechanically ventilated adult patients (>18 years old) admitted to ICU will be considered eligible if they have 2 or more of the following organ failures related to their acute illness:
  • - A PaO2/FiO2 ratio of <300;
  • - Clinical evidence of hypoperfusion defined as the need for vasopressor agents (norepinephrine, epinephrine, vasopressin, > 5 µg/kg/min of dopamine, or > 50 µg/min phenylephrine) for greater than or equal to 2 hours;
  • - In patients without known renal disease, renal dysfunction defined as a serum creatinine >171 µmol/L or a urine out-put of less than 500 ml/last 24 hours (or 80 ml/last 4 hours if a 24 hour period of observation not available). In pa-tients with acute on chronic renal failure (pre-dialysis), an absolute increase of > 80 µmol/L from baseline or pre-admission creatinine or a urine output of < 500 ml/last 24 hours (or 80 ml/last 4 hours) will be required;
  • - A platelet count of < 50 x109/l.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients will be excluded for any of the following reasons:
  • 1. > 24 hours from admission to ICU
  • 2. Patients who are moribund (not expected to be in ICU for more than 48 hours due to imminent death)
  • 3. A lack of commitment to full aggressive care (anticipated withholding or withdrawing treatments in the first week)
  • 4. Absolute contraindication to enteral nutrients (e.g., GI perforation, obstruction or no GI tract access for any reason)
  • 5. Patients with severe acquired brain injury
  • a)Significant head trauma (defined as an injury in the opinion of the investigator,
  • that represents a severe, disabling, or fatal brain injury)
  • b)Grade 4 or 5 subarachnoid haemorrhage
  • c) Stroke resulting in coma and intubation
  • d) Post-cardiac arrest with suspected significant an-oxic brain injury
  • 6. Seizure disorder requiring anticonvulsant medication
  • 7. Cirrhosis - Child’s class C liver disease
  • 8. Metastatic cancer or Stage IV Lymphoma with life expec-tancy < 6 months
  • 9. Routine elective cardiac surgery (patients with complicated peri-operative course requiring pressors, IABP, ventricular assist devices can be included)
  • 10. Patients with primary admission diagnosis of burns (> 30% body surface area
  • 11. Known or suspected hypersensitivity to component(s) of study medication
  • 12. Hereditary metabolic disorder in regards to component(s) of study medication
  • 13. Weight less than 50 kg or greater than 200 kg
  • 14. Pregnant patients or lactating with the intent to breastfeed. Females of child-bearing potential should have a negative urine or serum pregnancy test within 24 h prior to administration of study medication
  • 15. Previous randomization in this study
  • 16. Enrollment in a related ICU interventional study

研究者

发起方
Kingston General Hospital, Queen's University of Kingston

相似试验

REducing Deaths due to OXidative Stress The REDOXS©... | 临床试验